Table 3.
Risk categories based on evolving SNP sets and PCa detection rate in the placebo arm using GRS cutoff value of 1.5.
| Set of SNPs | No. (%) of subjects
|
% of PCa
|
% of high-grade PCa
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Remain lower | Reclassified | Remain higher | Remain lower | Reclassified | Remain higher | P-trend | Remain lower | Reclassified | Remain higher | P-trend | |
| 17 vs. 34 SNPs | 1168 (71.05%) | 232(14.11%) | 244 (14.84%) | 20.98 | 34.91 | 34.43 | 7.80×10−8 | 5.91 | 7.76 | 8.61 | 0.086 |
| 34 vs. 51 SNPs | 1172 (71.29%) | 198 (12.04%) | 274 (16.67%) | 21.42 | 27.27 | 38.32 | 5.58×10−9 | 5.63 | 8.59 | 9.12 | 0.019 |
| 51 vs. 68 SNPs | 1213 (73.78%) | 134 (8.15%) | 297 (18.07%) | 21.93 | 27.61 | 36.03 | 3.84×10−7 | 5.61 | 10.45 | 8.75 | 0.020 |
| 17, 34, 51, and 68 SNPsa | 1053 (64.05%) | 428 (26.03%) | 163 (9.91%) | 20.8 | 29.67 | 39.26 | 1.12×10−8 | 5.60 | 7.71 | 9.82 | 0.021 |
PCa: prostate cancer; SNP: single nucleotide polymorphism.
a
Reclassification of patient risk based on any GRS. For example, 1053 (64.05%) patients had lower risk for all of the four GRSs, 428 (26.03%) had reclassification for any of the GRSs, and 163 (9.91%) had higher risk for all of the four GRSs.